Synergistic activity of combination therapy with PEGylated pemetrexed and gemcitabine for an effective cancer treatment

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 94, Issue , 2015, Pages 83-93

  Vandana, Mallaredy ^a   Sahoo, Sanjeeb K ^a  

^a INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

Bioavailability; Combination therapy; Cytotoxicity; Gemcitabine; PEGylation; Pemetrexed

Indexed keywords

GEMCITABINE; MACROGOL; NANOCARRIER; PEMETREXED; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG CARRIER; DRUG COMBINATION; MACROGOL DERIVATIVE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL DEATH; CLONOGENIC ASSAY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; INTERNALIZATION; NON SMALL CELL LUNG CANCER; PINOCYTOSIS; PROTON NUCLEAR MAGNETIC RESONANCE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SYNTHESIS; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; BIOAVAILABILITY; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFRARED SPECTROSCOPY; LUNG NEOPLASMS; MEDICINAL CHEMISTRY; METABOLISM; PATHOLOGY; PHARMACEUTICS; PROCEDURES; REVERSED PHASE LIQUID CHROMATOGRAPHY; SIZE EXCLUSION CHROMATOGRAPHY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL AVAILABILITY; CARCINOMA, NON-SMALL-CELL LUNG; CELL DEATH; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG COMBINATIONS; DRUG SYNERGISM; HUMANS; LUNG NEOPLASMS; MICE, INBRED BALB C; PEMETREXED; PINOCYTOSIS; POLYETHYLENE GLYCOLS; PROTON MAGNETIC RESONANCE SPECTROSCOPY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TECHNOLOGY, PHARMACEUTICAL;

EID: 84929991740     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2015.04.017     Document Type: Article

References (47)

1. R. Arriagada, B. Bergman, A. Dunant, T. Le Chevalier, J.P. Pignon, and J. Vansteenkiste Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer N. Engl. J. Med. 350 2004 351 360
2. K. Azuma, T. Sasada, A. Kawahara, S. Takamori, S. Hattori, J. Ikeda, K. Itoh, A. Yamada, M. Kage, M. Kuwano, and H. Aizawa Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel Lung Cancer 64 2009 326 333
3. A. Chang Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC Lung Cancer 71 2011 3 10
4. G.J. Peters, C.L. van der Wilt, C.J. van Moorsel, J.R. Kroep, A.M. Bergman, and S.P. Ackland Basis for effective combination cancer chemotherapy with antimetabolites Pharmacol. Ther. 87 2000 227 253
5. A.A. Adjei Clinical studies of pemetrexed and gemcitabine combinations Ann. Oncol. 17 Suppl. 5 2006 v29 v32
6. E. Giovannetti, V. Mey, S. Nannizzi, G. Pasqualetti, L. Marini, M. Del Tacca, and R. Danesi Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells Mol. Pharmacol. 68 2005 110 118
7. T.M. De Pas, F. Toffalorio, E. Giovannetti, D. Radice, F. Russo, I. Angeli, G. Calamai, G. Spitaleri, C. Catania, C. Noberasco, A. Milani, G. Pelosi, R. Danesi, and F. De Braud Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer: a pharmacogenetic approach J. Thorac. Oncol. 6 2011 768 773
8. E. Giovannetti, V. Mey, R. Danesi, I. Mosca, and M. Del Tacca Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines Clin. Cancer Res. 10 2004 2936 2943
9. V. Mey, E. Giovannetti, F. De Braud, S. Nannizzi, G. Curigliano, F. Verweij, O. De Cobelli, S. Pece, M. Del Tacca, and R. Danesi In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients Br. J. Cancer 95 2006 289 297
10. C. Monnerat, T. Le Chevalier, K. Kelly, C.K. Obasaju, J. Brahmer, S. Novello, T. Nakamura, A.M. Liepa, L. Bozec, P.A. Bunn Jr., and D.S. Ettinger Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer Clin. Cancer Res. 10 2004 5439 5446
11. J. Ngeow, and C.K. Toh The role of pemetrexed combined with gemcitabine for non-small-cell lung cancer Curr. Drug Targets 11 2010 61 66
12. B.A. Teicher, V. Chen, C. Shih, K. Menon, P.A. Forler, V.G. Phares, and T. Amsrud Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts Clin. Cancer Res. 6 2000 1016 1023
13. S. Parveen, and S.K. Sahoo Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs Clin. Pharmacokinet. 45 2006 965 988
14. X. Pang, H.L. Du, H.Q. Zhang, Y.J. Zhai, and G.X. Zhai Polymer-drug conjugates: present state of play and future perspectives Drug Discov. Today 18 2013 1316 1322
15. G. Pasut, and F.M. Veronese PEG conjugates in clinical development or use as anticancer agents: an overview Adv. Drug Deliv. Rev. 61 2009 1177 1188
16. R. Duncan Polymer conjugates as anticancer nanomedicines Nat. Rev. Cancer 6 2006 688 701
17. M. Vandana, and S.K. Sahoo Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer Biomaterials 31 2010 9340 9356
18. M. Vandana, and S.K. Sahoo Reduced folate carrier independent internalization of PEGylated pemetrexed: a potential nanomedicinal approach for breast cancer therapy Mol. Pharm. 9 2012 2828 2843
19. P.C. Hermann, S.M. Trabulo, B. Sainz Jr., A. Balic, E. Garcia, S.A. Hahn, M. Vandana, S.K. Sahoo, P. Tunici, A. Bakker, M. Hidalgo, and C. Heeschen Multimodal treatment eliminates cancer stem cells and leads to long-term survival in primary human pancreatic cancer tissue xenografts PLoS One 8 2013 e66371
20. L. Santucci, A. Mencarelli, B. Renga, D. Ceccobelli, G. Pasut, F.M. Veronese, E. Distrutti, and S. Fiorucci Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice Anticancer Drugs 18 2007 1081 1091
21. L. Santucci, A. Mencarelli, B. Renga, G. Pasut, F. Veronese, A. Zacheo, A. Germani, and S. Fiorucci Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NO-pegylated epirubicin FASEB J. 20 2006 765 767
22. G. Pasut, F. Canal, L. Dalla Via, S. Arpicco, F.M. Veronese, and O. Schiavon Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid J. Control. Release 127 2008 239 248
23. J. Linares, M.C. Matesanz, M. Vila, M.J. Feito, G. Goncalves, M. Vallet-Regi, P.A. Marques, and M.T. Portoles Endocytic mechanisms of graphene oxide nanosheets in osteoblasts, hepatocytes and macrophages ACS Appl. Mater Interfaces 6 2014 13697 13706
24. D. Malide, and S.W. Cushman Morphological effects of wortmannin on the endosomal system and GLUT4-containing compartments in rat adipose cells J. Cell Sci. 110 Pt 22 1997 2795 2806
25. S. Kermorgant, and P.J. Parker Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation J. Cell Biol. 182 2008 855 863
26. S. Dharmawardhane, A. Schurmann, M.A. Sells, J. Chernoff, S.L. Schmid, and G.M. Bokoch Regulation of macropinocytosis by p21-activated kinase-1 Mol. Biol. Cell 11 2000 3341 3352
27. T. Lammers, V. Subr, K. Ulbrich, P. Peschke, P.E. Huber, W.E. Hennink, and G. Storm Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers Biomaterials 30 2009 3466 3475
28. T.K. Jain, J. Richey, M. Strand, D.L. Leslie-Pelecky, C.A. Flask, and V. Labhasetwar Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging Biomaterials 29 2008 4012 4021
29. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 22 1984 27 55
30. J. Carmichael, W.G. DeGraff, A.F. Gazdar, J.D. Minna, and J.B. Mitchell Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing Cancer Res. 47 1987 936 942
31. H.Q. Duong, J.S. Hwang, H.J. Kim, Y.S. Seong, and I. Bae BML-275, an AMPK inhibitor, induces DNA damage, G2/M arrest and apoptosis in human pancreatic cancer cells Int. J. Oncol. 41 2012 2227 2236
32. C. Guzman, M. Bagga, A. Kaur, J. Westermarck, and D. Abankwa ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays PLoS One 9 2014 e92444
33. T.Y. Yang, G.C. Chang, K.C. Chen, H.W. Hung, K.H. Hsu, C.H. Wu, G.T. Sheu, and S.L. Hsu Pemetrexed induces both intrinsic and extrinsic apoptosis through ataxia telangiectasia mutated/p53-dependent and -independent signaling pathways Mol. Carcinog. 52 3 2013 183 194
34. F. Pompeo, and D.E. Resasco Water solubilization of single-walled carbon nanotubes by functionalization with glucosamine Nano Lett. 2 2002 369 373
35. T. Min, H. Ye, P. Zhang, J. Liu, C. Zhang, W. Shen, W. Wang, and L. Shen Water-soluble poly(ethylene glycol) prodrug of pemetrexed: synthesis, characterization, and preliminary cytotoxicity J. Appl. Polym. Sci. 111 2009 444 451
36. N. Bertrand, and J.C. Leroux The journey of a drug-carrier in the body: an anatomo-physiological perspective J. Control. Release 161 2012 152 163
37. E. Markovsky, H. Baabur-Cohen, A. Eldar-Boock, L. Omer, G. Tiram, S. Ferber, P. Ofek, D. Polyak, A. Scomparin, and R. Satchi-Fainaro Administration, distribution, metabolism and elimination of polymer therapeutics J. Control. Release 161 2012 446 460
38. N.A. Franken, H.M. Rodermond, J. Stap, J. Haveman, and C. van Bree Clonogenic assay of cells in vitro Nat. Protoc. 1 2006 2315 2319
39. A. Munshi, M. Hobbs, and R.E. Meyn Clonogenic cell survival assay Methods Mol. Med. 110 2005 21 28
40. P. Parhi, C. Mohanty, and S.K. Sahoo Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy Drug Discov. Today 17 2012 1044 1052
41. C. Shih, V.J. Chen, L.S. Gossett, S.B. Gates, W.C. MacKellar, L.L. Habeck, K.A. Shackelford, L.G. Mendelsohn, D.J. Soose, V.F. Patel, S.L. Andis, J.R. Bewley, E.A. Rayl, B.A. Moroson, G.P. Beardsley, W. Kohler, M. Ratnam, and R.M. Schultz LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes Cancer Res. 57 1997 1116 1123
42. F. Greco, and M.J. Vicent Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines Adv. Drug Deliv. Rev. 61 2009 1203 1213
43. C.M. Hu, S. Aryal, and L. Zhang Nanoparticle-assisted combination therapies for effective cancer treatment Ther. Deliv. 1 2010 323 334
44. J. Kopecek Polymer-drug conjugates: origins, progress to date and future directions Adv. Drug Deliv. Rev. 65 2013 49 59
45. S. Chattopadhyay, R.G. Moran, and I.D. Goldman Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications Mol. Cancer Ther. 6 2007 404 417
46. J. Liu, H. Bauer, J. Callahan, P. Kopeckova, H. Pan, and J. Kopecek Endocytic uptake of a large array of HPMA copolymers: elucidation into the dependence on the physicochemical characteristics J. Control. Release 143 2010 71 79
47. V.N. Sumantran Cellular chemosensitivity assays: an overview Methods Mol. Biol. 731 2011 219 236